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Abstract
Oncolytic adenoviruses as a treatment for cancer have demonstrated limited clinical activity. Contributing to this may be the relevance of
preclinical animal models used to study these agents. Syngeneic mouse tumor models are generally non-permissive for adenoviral replication,
whereas human tumor xenograft models exhibit attenuated immune responses to the vector. The cotton rat (Sigmodon hispidus) is susceptible to
human adenovirus infection, permissive for viral replication and exhibits similar inflammatory pathology to humans with adenovirus replicating in
the lungs, respiratory passages and cornea. We evaluated three transplantable tumorigenic cotton rat cell lines, CCRT, LCRT and VCRT as models
for the study of oncolytic adenoviruses. All three cells lines were readily infected with adenovirus type-5-based vectors and exhibited high levels
of transgene expression. The cell lines supported viral replication demonstrated by the induction of cytopathogenic effect (CPE) in tissue culture,
increase in virus particle numbers and assembly of virions seen on transmission electron microscopy. In vivo, LCRT and VCRT tumors
demonstrated delayed growth after injection with replicating adenovirus. No in vivo antitumor activity was seen in CCRT tumors despite in vitro
oncolysis. Adenovirus was also rapidly cleared from the CCRT tumors compared to LCRT and VCRT tumors. The effect observed with the
different cotton rat tumor cell lines mimics the variable results of human clinical trials highlighting the potential relevance of this model for
assessing the activity and toxicity of oncolytic adenoviruses.
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The concept of using replicating lytic viruses as a treatment
for cancer is not new. A study of wild-type adenovirus as a
potential treatment for carcinoma of the uterine cervix was
reported in 1956, 3 years after the initial discovery of the virus
(Smith et al., 1956). Intratumoral injections of adenovirus
resulted in necrosis and cavity formation in 65% of treated
tumors and live adenovirus was recovered from two-thirds of
these patients suggesting that viral replication was occurring in⁎ Corresponding author. Fax: +1 301 402 1001.
E-mail address: jmorris@mail.nih.gov (J.C. Morris).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2007.07.022vivo. In contrast, no virus was isolated from the tumors of
patients treated with heat-inactivated virus. A second clinical
trial targeting a variety of tumors using adenovirus administered
by various routes was less successful, with only 2 of 14 patients
showing transient tumor regression and virus recovered from
only a single subject (Southam et al., 1956). Shortly thereafter,
advances in chemotherapy coupled with low viral yields due to
inefficient production techniques, and concerns over the risk of
viral dissemination and illness lead to the abandonment of
virotherapy.
Over the last decade, new understanding and developments
in molecular biology, virology and genetic engineering have led
to the reemergence of virotherapy as a potential treatment for
cancer. A number of replicating oncolytic adenovirus-based
132 J.C. Steel et al. / Virology 369 (2007) 131–142vectors have entered into clinical trials. These include the con-
ditionally replicating ONYX-015 (dl1520), CV706, CG7870,
Ad5-CD/TKrep and the Ad-OC-E1a vectors (Benjamin et al.,
2001; Bischoff et al., 1996; DeWeese et al., 2001; Freytag et al.,
2002; Small et al., 2006). Despite promising preclinical studies,
much of the initial excitement surrounding oncolytic adeno-
viruses has dampened with reports of a lack of tumor specificity
and few observed clinical responses when used as single agents
(Kirn, 2001).
The animal models used to evaluate these vectors may be a
significant factor in this discordance. Human adenoviruses are
unable to generate productive infections in most non-human
tissues limiting the usefulness of syngeneic immunocompetent
animal tumor models for the preclinical evaluation of these
agents. To date, the model of choice to study these agents has
been human tumor xenografts grown immunodeficient mice.
While immunodeficient mouse models are permissive to
adenoviral replication occurring in the xenograft, they do not
adequately assess the effect of viral dissemination and
replication on other tissues, and the host immune responses to
the virus and related toxicity. The inflammatory responses
induced by adenovirus are attenuated in these animals (Zhang et
al., 2001). In order to better assess factors important to the
efficacy of oncolytic adenovirus vectors, a preclinical model
that utilizes a syngeneic transplantable tumor in an immuno-
competent host would be advantageous.
Cotton rats (Sigmodon hispidus) are susceptible to infection
with a number of human respiratory viruses including Group C
adenoviruses (Niewiesk and Prince, 2002). Cotton rats exhibit
similar inflammatory pathology to humans with the virus
actively replicating in the lungs, tracheobronchial tree, nasal
passages and cornea (Pacini et al., 1984; Prince et al., 1993; TsaiFig. 1. Transgene expression in cotton rat tumor cells infected with a non-replicating a
and Saos-2 human cancer cell lines and TS/A and 15-12RM murine cancer cells w
expressing GFP was determined at 48 h by flow cytometry.et al., 1992). This has resulted in their use to assess the in vivo
spread and toxicity of adenoviral-based vectors prior to their use
in human gene therapy trials (Rojas-Martinez et al., 1998). Until
recently syngeneic transplantable cotton rat tumor cell lines
were unavailable. We studied three recently isolated tumori-
genic cell lines derived from spontaneous tumors of cotton rats,
CCRT, LCRT (Toth et al., 2005) and VCRT. Subcutaneous
implantation of these cell lines leads to the formation of tumors
in immunocompetent cotton rats. We evaluated each of the
tumor cell lines for permissiveness for adenoviral infection and
replication and assessed their efficacy as an in vivo model for
human adenovirus virotherapy for cancer.
Results
CCRT, LCRT and VCRT cotton rat tumor cells are readily
infected with adenovirus type-5 and express encoded
transgenes
The in vitro ability of the cotton rat tumor cell lines to be
infected with adenovirus was examined using Ad.GFP, an E1-
deleted replication-deficient vector expressing green fluorescent
protein. The cotton rat tumor cells were compared to mouse 15-
12RM sarcoma cells and TS/A mammary carcinoma cells and
human Saos-2 osteosarcoma and A549 lung cancer cells (Fig.
1). LCRT cells were the most readily infected of the cotton rat
tumors lines, with 99.3% of the cells expressing GFP at an MOI
of 100 PFU/cell as detected by flow cytometry. This was similar
to the human cell lines examined, with 99.5% of Saos-2 cells
and 98% of A549 cells expressing GFP. At MOI 100 PFU/cell,
VCRT and CCRT cells also showed high levels of expression
with 90.6% and 88.5% cells expressing GFP, respectively. Atdenovirus expressing GFP. CCRT, LCRTand VCRTcotton rat tumor cells, A549
ere infected with Ad.GFP at MOI 1, 10 and 100 and the percentage of cells
133J.C. Steel et al. / Virology 369 (2007) 131–142MOI 100 PFU/cell, 79.6% of TS/A cells and 70% 15-12RM
cells were positive for GFP.
Induction of cytopathogenic effect (CPE) in cotton rat tumor
cells by replicating adenovirus
Cotton rat tumor cell lines were examined for induction of
CPE after infection with the E1+ replicating Ad.OW94
expressing GFP. This was compared to cells infected with Ad.
GFP. Using fluorescence microscopy, GFP expression was
detected in each of the cotton rat tumor lines infected with Ad.Fig. 2. Lytic activity of Ad.OW94 (E1+) or Ad.GFP (E1−) on CCRT, LCRT, VCRTand
well plates and infected with Ad.GFP or Ad.OW94 at MOI of 10 or 100 PFU per ce
crystal violet, (B) examined microscopically for CPE and (C) examined by fluorescGFP; however, no CPE was observed at 7 days in any of the cell
lines infected Ad.GFP up to an MOI of 100 PFU/cell (Fig. 2).
Expression of GFP was observed in the cotton rat cell lines
infected with Ad.OW94 with marked CPE noted on micro-
scopic evaluation and staining with crystal violet. CPE was
observed in CCRT and LCRT cells infected with Ad.OW94 at
an MOI as low as 10 PFU/cell. In contrast, only limited CPE
was noted in VCRT cells infected with Ad.OW94 at this MOI;
however, at an MOI of 100 PFU/cell, high levels of GFP
expression were noted with significant CPE observed in all
three cotton rat cell lines 7 days after infection. As expected,HEK-293 cells. Each of the cell lines was seeded at 2×105 cells per well onto 6-
ll, or treated with a PBS control. After 7 days, cells were: (A) stained with 1%
ence microscopy for GFP expression.
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were almost completely lysed 72 h after infection with either
Ad.GFP or Ad.OW94.
Productive replication of adenovirus in cotton rat tumor cells
Viral burst assays were performed to determine the titer of
infective adenovirus produced by the cotton rat cells at a given
viral input. Following infection with Ad5.wt at MOI 0, 1, 10 or
100 PFU/cell, the quantity of adenovirus present in the cells was
assessed at 4 h and 72 h after initial infection by plaque titer.Fig. 3. Viral burst assays to determine the quantity of adenovirus released by (A) LC
adenovirus was assessed at 4 h and 72 h following infection with Ad5.wt at MOI 0Lysates of LCRT, VCRT and CCRT cells showed significantly
higher titers of adenovirus at 72 h than at 4 h after infection
indicating that replication of Ad5.wt was occurring in the cell
lines (Fig. 3). At an MOI of 1 PFU/cell, LCRT cells produced
significantly more adenovirus (57-fold) than either the CCRTor
VCRT cell lines (Pb0.05). At an MOI of 1 PFU/cell there was
no difference in production of adenovirus between the CCRT
and VCRT cells. At 100 PFU/cell there was no significant
difference between the amounts of adenovirus detected at 72 h
in CCRT or LCRT cells; however, VCRT cells consistently
produced lower viral titers.RT, (B) VCRT and (C) CCRT cells infected with Ad5.wt. The titer of infectious
, 1, 10 or 100. Error bars represent SD.
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cells in a time-dependent manner
CCRT, LCRT and VCRT cells infected with Ad5.wt at MOI
of 1 PFU/cell were examined at 4 h and 72 h post-infection by
transmission electron microscopy. No virions were detected
when each of the cell lines was examined 4 h after infection
(Figs. 4A, C and E). Infecting adenovirus would have
uncoated at this time point and the viral DNA released. In
contrast, mature appearing adenoviral particles were visible inFig. 4. Transmission electron micrographs of CCRT, LCRTand VCRTcells performed
and (E and F) VCRT cotton rat cell lines were infected with Ad5.wt at MOI 1 and e
infection. Arrows indicate adenoviral particles.the nucleus of cotton rat tumor lines at 72 h post-infection
(Figs. 4B, D and F).
Time-dependent increase in functional vector
We examined the functionality of the virus produced from
Ad.OW94 infected CCRT, LCRT and VCRT cells by transdu-
cing HeLa cell monolayers with cell-free supernatants obtained
from the cotton rat cell lines 5 h and 72 h after initial infection.
HeLa cells were examined 48 h later for expression of GFP. The4 h and 72 h after infection with adenovirus. (A and B), CCRT (C and D) LCRT
xamined by electron microscopy 4 h (A, C and E) and 72 h (B, D and F) after
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of higher titers of functional vector at 72 h than at 5 h, indicating
the production of functioning vector (Fig. 5). This finding was
consistent at all MOIs examined. The 72 h supernatants from
LCRT cells infected at an MOI of 100 PFU/cell resulted in the
greatest number of GFP-expressing HeLa cells (20.2%). This
represented a 10-fold increase in the number of GFP expressing
cells compared to 5 h. Supernatants removed at 72 h from
CCRT cells infected at an MOI of 300 PFU/cell resulted in
15.3% GFP expression by the HeLa cells. This was a 2.2-fold
increase in expression compared to cells transduced with the 5 h
supernatant. Supernatants from VCRT cells resulted in the
lowest number of GFP expressing HeLa cells (9.5%) even an
initial MOI of 300 PFU/cell, indicating less effective virusFig. 5. Time-dependent increase in functional viral titer after infection with replicating
and 72 h cell-free media supernatants were transferred to HeLa cell monolayers. Heproduction by VCRT cells. This was still 2.3-fold more than
observed with the 5 h supernatant.
Replication of adenovirus in cotton rat tumors in vivo
Subcutaneous CCRT, LCRT and VCRT tumors grown in
cotton rats and injected with Ad5.wt or non-replicating Ad.null
were excised on days 5 or 8 following the last injection and
were submitted for quantitative real-time PCR for detection of
adenoviral DNA. Viral genomes were detected in the CCRT,
LCRT and VCRT tumors at day 5; however, significantly
greater numbers of viral genomes were present in the tumors
injected with replicating Ad5.wt compared to the tumors
injected with non-replicating Ad.null (Fig. 6). No significantadenovirus. LCRT, VCRTand CCRTcells were infected with Ad.OW94. At 5 h
La cells were analyzed 24 h later for GFP expression.
Fig. 6. Quantification of adenoviral genomes in LCRT, VCRT and CCRT tumors in vivo. CCRT, LCRT and VCRT tumors were established in cotton rats and infected
with Ad5.wt or Ad.null. Five and eight days after the initial injection, tumors were removed from the animals from both groups, total DNA was extracted and the
number of adenovirus genomes measured using real-time PCR. The amount of virus was determined against a standard curve of known adenovirus. Error bars
represent the SD for 8 tumor samples.
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between any of the cotton rat cell lines at this time point.
Adenovirus was detected in tumors injected with Ad5.wt in
CCRT, LCRT and VCRT tumors excised 8 days after infection.
LCRT and VCRT tumors had means of 4×106 and 3×106
adenoviral genomes per ng of DNA at 8 days, respectively.
These levels were not significantly different compared to that
detected at day 5. CCRT tumors contained 2×103 viral
genomes per ng DNA at 8 days. This was decreased compared
to the numbers of viral genomes detected at 5 days (Pb0.05).
Negligible levels of adenovirus were detected in the LCRT and
CCRT tumors treated with Ad.null at 8 days. VCRT tumors
injected with Ad.null contained 8×102 genomes/ng DNA
which was significantly less than that detected in the Ad5.wt
injected VCRT tumors (Pb0.05).
Growth of LCRT and VCRT tumors was inhibited by
replicating adenovirus
To assess the activity of an oncolytic adenovirus on CCRT,
LCRT and VCRT tumors in vivo, each cotton rat tumor cell line
was infected ex vivo at their respective ID50 with Ad5.wt or Ad.
null and subcutaneously injected into the shoulder regions of
cotton rats. Animals injected with the respective uninfected
cotton rat tumor cell lines served as controls. Animals receiving
uninfected LCRT cells developed palpable tumors 6 days after
injection. At day 10, the mean tumor volume for LCRT cells
was 863 mm3 (Fig. 7A). Cotton rats injected with LCRT cells
infected with Ad.null also developed tumors by day 6, and by
day 10 the tumors had a mean volume of 526 mm3. Cotton rats
injected with the LCRT cells infected with Ad5.wt exhibited
delayed growth with the tumors becoming palpable at 16.5 days
post-implantation. On day 20, these tumors had a mean volume
of 354 mm3. The animals injected with unmodified LCRT cellsor LCRT cells infected with Ad.null were euthanized before day
20 due to rapid growth of tumor.
VCRT cells infected with Ad5.wt also exhibited growth
delay compared to untreated VCRTcells or VCRTcells infected
with Ad.null. Untreated VCRT tumors were palpable at a mean
of 11.3 days, while the Ad5.wt treated tumors became palpable
at 16.4 days (Fig. 7B). By day 20, the untreated tumors achieved
a mean volume of 213 mm3, while the Ad5.wt treated tumors
averaged 38 mm3. The Ad.null treated VCRT tumors appeared
at 14.3 days and grew to a mean volume of 99 mm3 by day 20.
CCRT tumors showed rapid growth regardless of any
treatment (Fig. 7C). Tumors were palpable in all treatment
groups at 9 days post-implantation. There was no significant
difference between the growth rates of the CCRT tumors
infected with Ad5.wt, Ad.null or the untreated CCRT cells at
any time point.
Discussion
Oncolytic adenoviruses for the treatment of cancer have
shown promise in preclinical studies; however, their transition
from the bench to success at the bedside has been inconsistent
(Nemunaitis et al., 2001; Habib et al., 2002; Freytag et al.,
2007). One possibility for this difference may be the limitations
of the preclinical animal models that are used to evaluate these
agents. Human adenoviruses do not effectively replicate in non-
human tissues and cell lines. To overcome this problem, these
vectors are commonly evaluated in immunodeficient mice
bearing human tumor xenografts. While these systems give
valuable information, they are limited because viral replication
is restricted to the tumor xenograft. Recently, a number of
reports have demonstrated variable levels of adenovirus
replication in certain mouse cell lines (Hallden et al., 2003),
primary swine cells (Jogler et al., 2006), some canine cell lines
Fig. 7. Growth curves for (A) LCRT, (B) VCRT and (C) CCRT tumors in vivo following infection with Ad.null (open circle), Ad5.wt (closed circle) or PBS (triangle).
Cotton rats were implanted subcutaneously with 1×106 infected tumor cells. Tumor size was measured daily with calipers and the tumor volume expressed the area of
a rotational ellipse. Error bars represent the SEM.
138 J.C. Steel et al. / Virology 369 (2007) 131–142(Ternovoi et al., 2005) and in Syrian hamsters (Thomas et al.,
2006).
In addition, adenoviruses elicit strong immune responses that
can impact on their efficacy as well as result in serious adverse
effects on the host (Yang et al., 1994; Ginsberg et al., 1990;
Everett et al., 2003). The attenuated inflammatory responses in
immunodeficient rodent models limit the ability to assess these
effects. The lungs, tracheobronchial tree, nasal passages and
cornea of cotton rats have been shown to be permissive for
replication of Group C adenoviruses and exhibit similar
pathology to that found in man (Pacini et al., 1984). As a
result, many currently consider the cotton rat as the model of
choice for assessing the safety and toxicity of replicating
adenoviruses (Shine et al., 1997).
The development of transplantable cotton rat tumor lines
represents an advance over immunodeficient rodent models to
assess the activity and potential toxicity of oncolytic adeno-
viruses. We examined three tumorigenic cotton rat cell lines toassess the levels of viral replication supported by these cells,
and the in vitro and in vivo oncolytic activity of adenovirus on
these tumors. Jogler et al. (2006) compared the replication of
adenovirus in primary cotton rat lung cells and found that they
showed comparable infectivity to human A549 cells, but were
superior to that of murine primary kidney cells. Similarly, we
found that all three cell lines studied were readily infected with
adenovirus. LCRT cells were comparable to human A549 cells
and more readily infected than the two murine cell lines that we
examined. The major determinant of permissiveness to
adenovirus infection in human cells is the expression of the
coxsackie-adenovirus receptor (CAR) (Bergelson et al., 1997).
Cells that lack or express low levels of the receptor show
resistance to infection with adenovirus (van't Hof and Crystal,
2001). Western blot using an antibody directed against human
CAR protein detected a strong band in LCRT cells that was not
found in CCRT or VCRT cells (data not shown). Whether the
detected protein plays a role in the uptake of adenovirus is
139J.C. Steel et al. / Virology 369 (2007) 131–142unknown, but it is intriguing that LCRT cells also showed the
greatest ability to be infected with adenovirus.
The ability of adenoviruses to replicate, induce cell lysis and
undergo secondary rounds of infection forms the basis of
oncolytic virotherapy. CCRT, LCRT and VCRT cells should
possess these characteristics to be useful as a model system for
cancer virotherapy. Over 72 h, each of the cell lines showed a 3
to 5 log increase in viral titers indicating active replication.
These results were confirmed by transmission electron micro-
scopy demonstrating the presence of virions. Four hours after
infection no intracellular viral particles could be demonstrated.
The absence of adenoviral particles at 4 h was expected as the
virions have entered the cells and unencapsidated (Leopold et
al., 1998). The appearance of viral particles in the nuclei at the
late time point is indicative of productive replication and
assembly of mature virions.
The cotton rat cells underwent viral induced cell lysis when
infected with replicating adenovirus. Cells infected with the
replicating GFP-expressing virus Ad.OW94 showed that each
of the cotton rat cell lines was readily infected and underwent
lysis. In contrast, cotton rat cells infected with non-replicating
E1-deleted Ad.GFP showed high levels of infection as
evidenced by expression of GFP, but showed no CPE and cell
lysis.
We also showed that fully functional adenovirus was
released from the infected cotton rat cell lines that could then
undergo secondary rounds of infection when transferred to
HeLa cells. Significantly greater levels of GFP expression were
seen in the HeLa cells exposed to the supernatants collected at
72 h compared to those exposed to supernatants collected at 5 h,
indicating that increased amounts of functional adenovirus were
released from the cotton rat cell lines over time. As expected, no
increase in the level of fluorescence over baseline was noted in
the HeLa cells exposed to supernatants from the cotton rat cells
infected with non-replicating Ad.GFP. In vitro, CCRT, LCRT
and VCRT cells fulfilled the requirements of a virotherapy
model allowing adenovirus to replicate, induce cell lysis, and
undergo secondary rounds of infection.
In vivo, significantly more adenovirus was detectable in
tumors injected with replication-competent Ad5.wt compared to
tumors treated with equal numbers of non-replicating Ad.null.
This was consistent for all of the cotton rat cell lines suggesting
that viral replication is occurring in vivo. The amount of virus
detected in the LCRTand VCRT tumors treated with the Ad5.wt
remained elevated out to day 8; however, CCRT tumors showed
a dramatic decrease in the number of viral genomes between 5
and 8 days. The conditions that mediate the rapid in vivo
clearance of adenovirus from CCRT tumors are unknown.
Elucidation of these factors may shed light as to why trials of
replication-competent adenoviruses have had limited success
despite showing significant antitumor activity in preclinical
xenograft models (McCormick, 2003).
In vivo, VCRT and LCRT cotton rat tumors treated with
Ad.5wt demonstrated growth delay compared to tumors treated
with either Ad.null or with PBS. LCRT tumors maintained
higher numbers of viral genomes over a longer period of time
and showed the greatest inhibition of growth. These results areconsistent with our in vitro findings that LCRT cells are more
readily infected by adenovirus and supported higher levels of
viral replication and oncolysis. Toth and colleges reported that
they were able to prevent or delay LCRT tumor formation and
growth using VRX-007, a replicating adenovirus that over-
expresses the adenoviral death protein (Toth et al., 2005). They
had previously reported that VRX-007 induces greater cell lysis
and viral spread compared to Ad5.wt (Doronin et al., 2003).
This may account for the prevention of tumor formation in their
study whereas our results using Ad5.wt showed that while the
virus was able to delay in tumor formation, it was unable to
completely prevent the formation of tumors. These differences
also highlight the potential of this animal model to study
improvements or modifications of adenoviral vectors that may
enhance their oncolytic activity, such as over-expression of
“death” proteins, suicide genes or immune stimulating genes,
designed to increase the therapeutic potential of virotherapy.
In vivo, VCRT tumors also maintained a significant viral
load out to 8 days suggesting viral replication; however, the
oncolytic sensitivity of VCRT tumors to Ad5wt was less than
that of LCRT tumors. This was consistent with the in vitro
findings in which VCRT cells were less readily infected and
produced lower viral titers compared to LCRT cells. CCRT
tumors treated with Ad5.wt did not demonstrate any inhibition
of growth when compared to controls in two separate
experiments. In vitro, CCRT cells readily infect with adenovirus
and produced significant viral titers; however, adenovirus is
rapidly cleared from CCRT tumors in vivo. The in vitro as
compared to in vivo disparity of the oncolytic effect on CCRT
cells highlights the need for permissive immunocompetent
animal tumor models to assess the effects of in vivo tumor
dynamics and a functional immune system on replicating
viruses.
Replicating adenoviruses efficiently infect, productively
replicate and induced oncolysis in three transplantable tumori-
genic cotton rat cell lines. We demonstrated that, despite the
permissiveness of the cotton rat tumor lines to adenovirus
replication in vitro, a variable antitumor effect was observed in
vivo. These results correspond with the variable and limited
tumor responses reported in most human clinical trials
highlighting the relevance of the cotton rat tumor model for
assessing replication-competent adenovirus vector for oncolytic
therapy of tumors.
Materials and methods
Cells
Three transplantable tumorigenic cell lines, CCRT, LCRT
and VCRT, were isolated from spontaneous tumors occurring in
different animals from an inbred colony of cotton rats (S.
hispidus). CCRT cells represent an osteosarcoma, LCRT cells
were derived from a mammary fibrosarcoma, and VCRT cells
were isolated from a spindle cell sarcoma of the mandible.
These tumor cell lines were maintained in high-glucose
Dulbecco's modified Eagle's medium (DMEM; Biosource,
Rockville, MD) with 10% fetal bovine serum (FBS; Gemini,
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kidney (HEK)-293 cells, human A549 lung cancer cells, human
Saos-2 osteosarcoma cells and HeLa cells were obtained from
American Type Culture Collection (ATCC; Manassas, VA) and
were grown in high-glucose DMEM with 10% FBS and
gentamicin. The murine fibrosarcoma cell line 15-12RM
(Matsui et al., 1999) and the murine breast cancer cell line
TS/A (Nanni et al., 1983) were gifts of Jay A. Berzofsky (NCI,
Bethesda, MD) and Patrizia Nanni (University of Bologna,
Italy), respectively and were grown in high-glucose DMEM
with 10% FBS and gentamicin. All cell cultures were
maintained at 37 °C and 5% CO2.
Adenoviral vectors
Wild-type adenovirus type-5 was obtained from ATCC (VR-
5) (Rowe et al., 1953); Ad.GFP, an E1-deleted adenovirus
expressing enhanced green fluorescent protein under the control
of the cytomegalovirus IE (CMV-IE) promoter, was purchased
from Quantum Biotechnologies (Quebec, Canada). Ad.null, an
“empty” control vector, containing deletions in E1 and E3 and
the CMV-IE promoter with no transgene, was generated by
homologous recombination using the AdMax system (Micro-
bix, Toronto, Canada; Sakai et al., 2004). Ad.OW94 contains in
the E1 region a GFP-IRES-Ad5 E1 expression cassette driven
by the human CMV-IE promoter flanked upstream by the Ad5
packaging sequence and downstream by the Ad5 pIX. Ad.
OW94 was generated by homologous recombination of pAd.
CMV-GFP and pBHG10 in 293 cells, as described previously
(Jogler et al., 2006). All viruses were expanded on HEK-293
cells, purified by two-step CsCl density-gradient ultracentrifu-
gation, dialyzed, titered by serial dilution, quantified as plaque
forming units (PFU)/mL on HEK-293 cells and stored at
−70 °C (Graham and Prevec, 1995).
Animals
All studies were carried out on an Animal Care and Use
Committee approved protocol (Virion Systems, Inc., Rockville,
MD). Inbred cotton rats weighing 150–200 g were maintained
under clean, light and temperature controlled conditions,
housed two per cage with access to food and water ad libitum.
Adenoviral infections
To determine the efficiency of adenoviral infection and
transgene expression in vitro, the cotton rat tumor cell lines
were compared to human A549 and Saos-2 cells, and murine
15-12RM and TS/A cells using Ad.GFP as a reporter. Briefly,
each cell line was seeded onto 6-well plates at 1×106 cells/well
and infected with Ad.GFP at multiplicities of infection (MOI) of
0, 1, 10, 30, 100 or 300 PFU/cell. After 6 h, the cells were
washed with phosphate buffered saline (PBS; Biosource) and
the media replaced. The cells were incubated for an additional
36 h, trypsinized, washed and analyzed for expression of GFP
using a FACSCalibur flow cytometer (Becton-Dickinson
Immunocytometry Systems; Mansfield, MA).Determination of cytopathogenic effect (CPE)
CCRT, LCRT, VCRT and HEK-293 cells were seeded onto
6-well plates at 2×105 cells/well and infected with Ad.GFP or
Ad.OW94 at MOI 0, 10 or 100 PFU/cell. After 4 h the cells
were washed three times with PBS, the media replaced and the
cells incubated at 37 °C. Seven days later, the cells were
examined microscopically for lysis and stained with 1% crystal
violet in 10% formaldehyde and 20% ethanol for 15 min. The
plates were washed with ddH2O, air-dried and examined.
Viral burst assay
CCRT, LCRT and VCRT cells were seeded in duplicate onto
6-well plates at 3×105 cells/well and infected with Ad5.wt at
MOI 0, 1, 10 or 100 PFU/cell. The cells were incubated at 37 °C
for 4 h, at which point the media were removed, the cells
washed 3 times with PBS and fresh media added. Adenovirus
was harvested from one duplicate set of plates by scraping cells,
freezing and thawing three times and passing the lysate through
a 0.22 μm filter (Millipore, Billerica, MA). The lysate was
stored at −70 °C. The other duplicate set of plates was similarly
harvested and stored at 72 h. The amount of virus at each time
point (4 h and 72 h) was quantified by plaque titer on HEK-293
cells.
Time-dependent viral release assay
CCRT, LCRTand VCRTcells were seeded onto 6-well plates
at 3×105 cells/well in duplicate plates and infected with either
Ad.GFP or Ad.OW94 at MOI 0, 1, 10, 30, 100 or 300 PFU/cell.
The cells were incubated at 37 °C for 4 h, at which point the
media were removed, the cells were washed 5 times with PBS
and 2 mL fresh media was added back. The cells were incubated
for an additional 1 h. The media were removed, passed though a
0.22 μM filter and stored at −70 °C. Two milliliters of media
was added back to the cells and they were incubated for an
additional 48 h. The media were then removed, filtered and
stored at −70 °C. One milliliter of these filtrates was added to
wells in 6-well plates containing 3×105 HeLa cells/well. At
48 h, the HeLa cells were trypsinized, washed and assayed for
GFP expression by flow cytometry.
Transmission electron microscopy
CCRT, LCRT and VCRT cells were seeded at 1×107 cells
onto 75 cm2 tissue culture flasks in duplicate and infected with
Ad5.wt at 1 PFU/cell. Following a 4 h incubation at 37 °C, the
media were removed and the cells were washed 3 times. In one
set of flasks, the cells were fixed with 4% glutaraldehyde and
incubated at 4 °C for 1 h. The cells were dislodged using a
scraper, pelleted and resuspended in 500 μL 4% glutaraldehyde
and stored at 4 °C. The other set of flasks was refreshed with
media and the cells incubated for an additional 72 h, at which
point the cells were similarly fixed and harvested. Cells from
both sets of flasks were then double-fixed in PBS-buffered
glutaraldehyde (2.5%) and osmium tetroxide (0.5%), dehydrated
141J.C. Steel et al. / Virology 369 (2007) 131–142and embedded in Spurr's epoxy resin. Ultrathin sections (90 nm)
were made and double-stained with uranyl acetate and lead
citrate and viewed using a Philips CM10 transmission electron
microscope (Electronic Instruments, Mahwah, NJ).
Establishment of subcutaneous tumors in cotton rats and
intratumoral injection of adenovirus
CCRT, LCRT and VCRT tumors were established by
subcutaneous injection of 1×106 tumor cells into the shoulder
regions of cotton rats. When the tumors reached a volume of
100–200 mm3 (day 6), they were injected with Ad5.wt 2.5×108
PFU or Ad.null 2.5×108 PFU in 100 μL PBS, or 100 μL PBS
daily for 4 days using a tuberculin syringe and a 27-gauge
needle by injecting in a separate quadrant of the tumor each day.
Four animals from each group were euthanized 24 h and 96 h
after the last injection. The tumors were excised, dissected free
of surrounding tissue and stored in liquid nitrogen until
processing.
Quantitation of adenovirus by real-time PCR
Quantitative PCR was used to measure the amount of
adenovirus in tissue samples (Wildner and Morris, 2002). Total
DNA was extracted from the CCRT, LCRT and VCRT tumors
using a DNeasy tissue kit (Qiagen Inc., Valencia, CA) and
quantified by spectrophotometer (A260). A quantitative Ad5
real-time PCR assay was performed using the following primers
and probe: Ad5 33414 fwd-GTAATTCACCACCTCCCGGTA,
Ad5 33562 rev-GGCTCTCCACTGTCATTGTTC, Ad5 probe-
ACCTCTGATTAAACATGGCGCCATCC (FAM labeled 5′,
TAMRA quencher 3′). DNA was amplified using 100 nM of
each primer and 200 nM of the probe using the following
cycling conditions: 2 min at 50 °C, 10 min at 95 °C, 45 cycles of
15 s at 95 °C (denaturation) and 45 cycles of 1 min at 63 °C
(extension/annealing) in an ABI 7700 DNA sequencer (Applied
Biosystems, Foster City, CA). A standard curve was generated
using pre-titered adenovirus standards ranging from 101 to 107
PFU. PCR reactions for each sample were performed in
triplicate using the same oligonucleotide primers and fluor-
escent probe, reaction conditions and cycling.
Effect of adenovirus on cotton rat tumors in vivo
CCRT, LCRT or VCRT cells were seeded at 1×107 cells/
flask into 175 cm2 tissue culture flasks. The cells were infected
with Ad5.wt or non-replicating Ad.null at the infectious dose-
50% (ID50) and incubated for 6 h at 37 °C. ID50 was determined
from the tissue culture infectious dose-50 (TCID50) for each of
the cotton rat cell lines infected with Ad5.wt. Briefly, 96-well
plates were seeded with 1×104 cells/well. Serial dilutions of
Ad5.wt were added to the wells in each column. The plates were
then incubated at 37 °C. Each well was examined daily for 14
days for cytopathogenic effect (CPE). The TCID50 value was
calculated using the Reed–Muench formula (Reed and Muench,
1938). The respective ID50s of the LCRT, CCRT and VCRT
cells that were used to infect the cells lines were 4, 8 and 20PFU/cell (results not shown). The cells were washed 3 times
with PBS, trypsinized and counted. Cotton rats were sub-
cutaneously injected in the shoulder regions with 1×106 tumor
cells. The animals were examined daily for tumor growth.
Tumors were measured with Vernier calipers and tumor size
was expressed as the volume of a rotational ellipse (Dethlefsen
et al., 1968).
Statistics and software
Statistical analysis was preformed using Student's t-test
using SigmaStat version 3.1 statistical software (Systat, Point
Richmond, CA). In vitro data are presented as mean±SD; in
vivo data are represented as mean±SEM.
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